Screener
BridgeBio Pharma BBIO Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EquityMethodInvestments.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Inventories | 52,842 | 26,753 |
| Prepaid expenses and other current assets | 65,652 | 44,070 |
| Total current assets | 1,093,138 | 797,749 |
| Equity method investments | 55,095 | 79,972 |
| Property and equipment, net | 5,226 | 5,366 |
| Operating lease right-of-use assets | 17,079 | 8,149 |
| Intangible assets, net | 26,641 | 28,077 |
| Other assets | 20,120 | 16,712 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's equity method investments?
- BridgeBio Pharma (BBIO) reported equity method investments of $55.1M in Q2 2026.
- How has BridgeBio Pharma's equity method investments changed year-over-year?
- BridgeBio Pharma's equity method investments decreased by 49.0% year-over-year, from $108M to $55.1M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about BridgeBio Pharma's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude